Cargando…

Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma

BACKGROUND: Medulloblastoma (MB) comprises four subtypes of which group 3 MB are the most aggressive. Although overall survival for MB has improved, the outcome of group 3 MB remains dismal. C-MYC (MYC) amplification or MYC overexpression which characterizes group 3 MB is a strong negative prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Tiffany S Y, Picard, Daniel, Hawkins, Cynthia E, Lu, Mei, Pfister, Stefan, Korshunov, Andrey, Roussel, Martine F, Wechsler-Reya, Robert J, Henkin, Jack, Bouffet, Eric, Huang, Annie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890793/ https://www.ncbi.nlm.nih.gov/pubmed/33629064 http://dx.doi.org/10.1093/noajnl/vdab002

Ejemplares similares

Characterization of G-CSF receptor expression in medulloblastoma
por: Paul, Megan Rose, et al.
Publicado: (2020)

Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma
por: Krausert, Sonja, et al.
Publicado: (2022)

The long non-coding RNA SPRIGHTLY and its binding partner PTBP1 regulate exon 5 skipping of SMYD3 transcripts in group 4 medulloblastomas
por: Lee, Bongyong, et al.
Publicado: (2022)

ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma
por: Nasir, Aishah, et al.
Publicado: (2021)

Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model
por: Simovic, Milena, et al.
Publicado: (2021)

Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse
por: Richardson, Stacey, et al.
Publicado: (2021)

TGF-β promotes microtube formation in glioblastoma through thrombospondin 1
por: Joseph, Justin V, et al.
Publicado: (2021)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Expression of cell type incongruent alpha-cardiac actin 1 subunit in medulloblastoma reveals a novel mechanism for cancer cell survival and control of migration
por: Suresh, Rahul, et al.
Publicado: (2021)

Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma
por: Pereira, Victor, et al.
Publicado: (2021)

Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma
por: Badodi, Sara, et al.
Publicado: (2022)

ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination
por: Jones, Jill K, et al.
Publicado: (2023)

Update on molecular and genetic alterations in adult medulloblastoma
por: Kool, Marcel, et al.
Publicado: (2012)

Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression
por: Wynn, Daniel T, et al.
Publicado: (2022)

Pediatric glioma and medulloblastoma risk and population demographics: a Poisson regression analysis
por: Muskens, Ivo S, et al.
Publicado: (2020)

MEDB-47. CD4+ T cells restrict medulloblastoma growth and dissemination
por: Eisemann, Tanja, et al.
Publicado: (2022)

Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma
por: Eisemann, Tanja, et al.
Publicado: (2022)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

OMIC-03. TRANSLATIONAL CONTROL IN MYC AND MYCN MEDULLOBLASTOMA
por: Schmidt, Christin, et al.
Publicado: (2021)

Mouse medulloblastoma driven by CRISPR activation of cellular Myc
por: Vo, BaoHan T., et al.
Publicado: (2018)

BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS
por: Yang, Rui, et al.
Publicado: (2021)

Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells
por: Kawauchi, D, et al.
Publicado: (2017)

Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma
por: McCabe, Martin G., et al.
Publicado: (2011)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Molecular subgrouping of medulloblastoma based on few-shot learning of multitasking using conventional MR images: a retrospective multicenter study
por: Chen, Xi, et al.
Publicado: (2020)

Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors
por: Ho, Vincent K Y, et al.
Publicado: (2022)

Sox2(+) cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence
por: Treisman, Daniel M, et al.
Publicado: (2019)

MEDB-33. The landscape of ecDNA in medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples
por: Northcott, Paul A., et al.
Publicado: (2011)

Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane
por: Maloney, S L, et al.
Publicado: (2009)

Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma
por: Kameda-Smith, Michelle M., et al.
Publicado: (2022)

Abnormalities of structural brain connectivity in pediatric brain tumor survivors
por: Oyefiade, Adeoye, et al.
Publicado: (2022)

Medulloblastoma: advances and challenges
por: Roussel, Martine F., et al.
Publicado: (2011)

MBRS-16. MYC REGULATED LONG NONCODING RNA LNC-HLX-2–7 IS A PUTATIVE MOLECULAR MARKER AND A THERAPEUTIC TARGET FOR GROUP 3 MEDULLOBLASTOMAS IN CHILDREN
por: Katsushima, Keisuke, et al.
Publicado: (2020)

MEDB-66. Investigating intra-tumoral heterogeneity of extrachromosomal DNA in SHH medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022)

Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer
por: Zeng, C, et al.
Publicado: (2013)

Modeling pediatric medulloblastoma
por: Roussel, Martine F., et al.
Publicado: (2019)

Author Correction: Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma
por: Kameda-Smith, Michelle M., et al.
Publicado: (2023)

The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations
por: Deng, Jiaojiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sjl5m2ik1s7ls6fo1fj2tsbkuq